PET/CT in Gynecologic Cancer: Present Applications and Future Prospects-A Clinician's Perspective

Obstetrics and Gynecology Clinics of North America

Volumn 38, Issue 1, 2011, Pages 1-21

  Amit, Amnon ^a   Schink, Julian ^b   Reiss, Ari ^a,c   Lowenstein, Lior ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Best practice; Cross sectional imaging; Gynecologic cancer

Indexed keywords

BRCA2 PROTEIN; CA 125 ANTIGEN; CISPLATIN; DOXORUBICIN; ESTRADIOL; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX; TOPOTECAN; WART VIRUS VACCINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CURETTAGE; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYSTERECTOMY; INCIDENCE; LAPAROSCOPIC SURGERY; OVARY CANCER; OVERALL SURVIVAL; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATIENT CARE; PELVIS LYMPHADENECTOMY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX CANCER;

EID: 79952668645     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2011.02.001     Document Type: Review

References (103)

1. Ellenson L.H., Wu T.C. Focus on endometrial and cervical cancer. Cancer Cell 2004, 5(6):533-538.
2. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
3. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
4. Lagasse L.D., Creasman W.T., Shingleton H.M., et al. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol 1980, 9(1):90-98.
5. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18(8):1606-1613.
6. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999, 340(15):1144-1153.
7. Sedlis A., Bundy B.N., Rotman M.Z., et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 1999, 73(2):177-183.
8. Grigsby P.W., Siegel B.A., Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001, 19(17):3745-3749.
9. Burnett A.F., Roman L.D., O'Meara A.T., et al. Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol 2003, 88(3):419-423.
10. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005, 23(21):4626-4633.
11. Whitcomb B.P. Gynecologic malignancies. Surg Clin North Am 2008, 88(2):301-317. vi.
12. Magne N., Chargari C., Vicenzi L., et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev 2008, 34(8):671-681.
13. Grigsby P.W. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging 2008, 8:146-155.
14. Narayan K., Hicks R.J., Jobling T., et al. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer 2001, 11(4):263-271.
15. Singh A.K., Grigsby P.W., Dehdashti F., et al. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003, 56(2):489-493.
16. 18 F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep 2002, 9(6):1289-1292.
17. Yen T.C., Ng K.K., Ma S.Y., et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003, 21(19):3651-3658.
18. Amit A., Beck D., Lowenstein L., et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006, 100(1):65-69.
19. Grigsby P.W. PET/CT imaging to guide cervical cancer therapy. Future Oncol 2009, 5(7):953-958.
20. Rose P.G., Adler L.P., Rodriguez M., et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999, 17(1):41-45.
21. 18 F]-fluoro-2-deoxy-d-glucose-positron emission tomography. Cancer 2005, 104(11):2484-2491.
22. Loft A., Berthelsen A.K., Roed H., et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007, 106(1):29-34.
23. Qiu J.T., Ho K.C., Lai C.H., et al. Supraclavicular lymph node metastases in cervical cancer. Eur J Gynaecol Oncol 2007, 28(1):33-38.
24. Tsai C.S., Chang T.C., Lai C.H., et al. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT. Int J Radiat Oncol Biol Phys 2004, 58(5):1506-1512.
25. Belhocine T., De Barsy C., Hustinx R., et al. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002, 29(9):1132-1139.
26. Brooks R.A., Rader J.S., Dehdashti F., et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009, 112(1):104-109.
27. 18 F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004, 22(11):2167-2171.
28. Tran B.N., Grigsby P.W., Dehdashti F., et al. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 2003, 90(3):572-576.
29. Bodurka-Bevers D., Morris M., Eifel P.J., et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000, 78(2):187-193.
30. Chien C.R., Ting L.L., Hsieh C.Y., et al. Post-radiation Pap smear for Chinese patients with cervical cancer: a ten-year follow-up. Eur J Gynaecol Oncol 2005, 26(6):619-622.
31. Shield P.W., Daunter B., Wright R.G. Post-irradiation cytology of cervical cancer patients. Cytopathology 1992, 3(3):167-182.
32. 18 F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 2009, 50(Suppl 1):64S-73S.
33. Morice P., Deyrolle C., Rey A., et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004, 15(2):218-223.
34. Permuth-Wey J., Sellers T.A. Epidemiology of ovarian cancer. Methods Mol Biol 2009, 472:413-437.
35. Auersperg N., Wong A.S., Choi K.C., et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22(2):255-288.
36. Riman T., Nilsson S., Persson I.R. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004, 83(9):783-795.
37. Edwards B.K., Brown M.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97(19):1407-1427.
38. Ziogas A., Gildea M., Cohen P., et al. Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000, 9(1):103-111.
39. Malander S., Rambech E., Kristoffersson U., et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006, 101(2):238-243.
40. Siskind V., Green A., Bain C., et al. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 2000, 11(2):106-110.
41. Schutter E.M., Kenemans P., Sohn C., et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994, 74(4):1398-1406.
42. Schutter E.M., Sohn C., Kristen P., et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol 1998, 69(1):56-63.
43. Burghardt E., Lahousen M., Stettner H. The significance of pelvic and para-aortic lymphadenectomy in the operative treatment of ovarian cancer. Baillieres Clin Obstet Gynaecol 1989, 3(1):157-165.
44. Burghardt E., Pickel H., Lahousen M., et al. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986, 155(2):315-319.
45. Dauplat J., Hacker N.F., Nieberg R.K., et al. Distant metastases in epithelial ovarian carcinoma. Cancer 1987, 60(7):1561-1566.
46. Julian C.G., Goss J., Blanchard K., et al. Biologic behavior of primary ovarian malignancy. Obstet Gynecol 1974, 44(6):873-884.
47. Brooks S.E. Preoperative evaluation of patients with suspected ovarian cancer. Gynecol Oncol 1994, 55(3 Pt 2):S80-S90.
48. Curtin J.P. Management of the adnexal mass. Gynecol Oncol 1994, 55(3 Pt 2):S42-S46.
49. Ind T.E., Granowska M., Britton K.E., et al. Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe. Br J Cancer 1994, 70(6):1263-1266.
50. Kinkel K., Hricak H., Lu Y., et al. US characterization of ovarian masses: a meta-analysis. Radiology 2000, 217(3):803-811.
51. Hewitt M.J., Anderson K., Hall G.D., et al. Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG 2007, 114(1):46-50.
52. Goff B.A., Matthews B.J., Larson E.H., et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007, 109(10):2031-2042.
53. Le T., Adolph A., Krepart G.V., et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002, 85(2):351-355.
54. Eisenkop S.M. Commenting on centralizing surgery for gynecologic oncology: a strategy assuring better quality treatment? (89:4-8) by Karsten Munstedt, et al. Gynecol Oncol 2004, 94(2):605-606. [author reply: 606-7].
55. Munstedt K., von Georgi R., Misselwitz B., et al. Centralizing surgery for gynecologic oncology-a strategy assuring better quality treatment?. Gynecol Oncol 2003, 89(1):4-8.
56. Boente M.P., Chi D.S., Hoskins W.J. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998, 25(3):326-334.
57. Chi D.S., Eisenhauer E.L., Lang J., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 2006, 103(2):559-564.
58. Eisenkop S.M., Spirtos N.M., Lin W.C. " Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 2006, 103(1):329-335.
59. Winter W.E., Maxwell G.L., Tian C., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2008, 26(1):83-89.
60. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008, 108(2):276-281.
61. Redman C.W., Warwick J., Luesley D.M., et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994, 101(2):142-146.
62. Aletti G.D., Gostout B.S., Podratz K.C., et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006, 100(1):33-37.
63. van der Burg M.E., van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995, 332:629-634.
64. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004, 351(24):2489-2497.
65. Wenzel L., Huang H.Q., Monk B.J., et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2005, 23(24):5605-5612.
66. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21(17):3194-3200.
67. Greimel E.R., Bjelic-Radisic V., Pfisterer J., et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 2006, 24(4):579-586.
68. Einzig A.I., Wiernik P.H., Sasloff J., et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992, 10(11):1748-1753.
69. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S161-S192.
70. Berek J.S., Trope C., Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999, 10(Suppl 1):3-7.
71. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334(1):1-6.
72. Risum S., Hogdall C., Loft A., et al. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?. Gynecol Oncol 2010, 116(3):395-398.
73. Risum S., Hogdall C., Loft A., et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol 2007, 105(1):145-149.
74. Gu P., Pan L.L., Wu S.Q., et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009, 71(1):164-174.
75. Moore R.G., MacLaughlan S., Bast R.C. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 2010, 116(2):240-245.
76. Agress H., Cooper B.Z. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004, 230(2):417-422.
77. Milam R.A., Milam M.R., Iyer R.B. Detection of early-stage ovarian cancer by FDG-PET-CT in a patient with BRCA2-positive breast cancer. J Clin Oncol 2007, 25(35):5657-5658.
78. Barnholtz-Sloan J.S., Schwartz A.G., Qureshi F., et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003, 189(4):1120-1127.
79. Tailor A., Bourne T.H., Campbell S., et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003, 21(4):378-385.
80. Karlan B.Y., Baldwin R.L., Lopez-Luevanos E., et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999, 180(4):917-928.
81. Olivier R.I., Lubsen-Brandsma M.A., Verhoef S., et al. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006, 100(1):20-26.
82. Gadducci A., Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol 2009, 71(1):43-52.
83. Jung D.C., Kang S., Kim M.J., et al. Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer. Eur Radiol 2010, 20(1):100-107.
84. Gadducci A., Cosio S., Zola P., et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer 2007, 17(1):21-31.
85. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
86. Schink J.C., Rademaker A.W., Miller D.S., et al. Tumor size in endometrial cancer. Cancer 1991, 67(11):2791-2794.
87. Karlsson B., Granberg S., Wikland M., et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding-a Nordic multicenter study. Am J Obstet Gynecol 1995, 172(5):1488-1494.
88. Gupta J.K., Chien P.F., Voit D., et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002, 81(9):799-816.
89. Tabor A., Watt H.C., Wald N.J. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol 2002, 99(4):663-670.
90. Hricak H., Rubinstein L.V., Gherman G.M., et al. MR imaging evaluation of endometrial carcinoma results of an NCI cooperative study. Radiology 1991, 179(3):829-832.
91. Connor J.P., Andrews J.I., Anderson B., et al. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000, 95(5):692-696.
92. Manfredi R., Mirk P., Maresca G., et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004, 231(2):372-378.
93. Rockall A.G., Sohaib S.A., Harisinghani M.G., et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005, 23(12):2813-2821.
94. Sugiyama T., Nishida T., Ushijima K., et al. Detection of lymph node metastasis in ovarian carcinoma and uterine corpus carcinoma by preoperative computerized tomography or magnetic resonance imaging. J Obstet Gynaecol (Tokyo 1995) 1995, 21(6):551-556.
95. Suzuki R., Miyagi E., Takahashi N., et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007, 17(4):890-896.
96. 18 F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. Am J Roentgenol 2008, 190(6):1652-1658.
97. Walker J.L., Piedmonte M.R., Spirtos N.M., et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009, 27(32):5331-5336.
98. ASTEC study group, Kitchener H., Swart A.M., et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009, 373(9658):125-136.
99. Saga T., Higashi T., Ishimori T., et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003, 17(3):197-203.
100. Park J.Y., Kim E.N., Kim D.Y., et al. Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients. Int J Gynecol Cancer 2008, 18(6):1332-1338.
101. Kitajima K., Murakami K., Yamasaki E., et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging 2009, 36(3):362-372.
102. Yoshida Y., Kurokawa T., Sawamura Y., et al. The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol 2007, 104(3):764-766.
103. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009, 105(2):103-104.